VYGR · XBRL financial data

Voyager Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (VYGR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	171,128	37,415	40,907	250,008	80,001	40,374
Research and development	108,753	73,787	60,764	92,172	127,368	134,674
General and administrative	34,991	37,246	30,980	35,822	35,920	37,544
Total operating expenses	143,744	111,033	91,744	127,994	163,288	172,218
Operating income (loss)	27,384	(73,618)	(50,837)	122,014	(83,287)	(131,844)
Other income (expense)	7,698	2,811	2,653	3	622	1,649
Income tax expense (benefit)	—	—	16	1,408	665	144
Net income (loss)	36,741	(71,197)	(46,408)	132,330	(65,002)	(119,721)
Earnings per share, basic USD per share	0.99	(1.89)	(1.21)	3.08	(1.13)	(2.04)
Earnings per share, diluted USD per share	0.98	(1.89)	(1.21)	2.97	(1.13)	(2.04)
Weighted average shares, basic thousands of shares	37,132	37,669	38,357	43,021	57,668	58,691
Weighted average shares, diluted thousands of shares	37,349	37,669	38,357	44,569	57,668	58,691

Fiscal years (VYGR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	104,440	117,433	98,959	68,802	71,367	65,300
Marketable securities	76,698	15,106	19,889	162,073	195,317	131,147
Marketable securities, non-current	—	—	—	—	65,704	5,244
Prepaid and other current assets	8,619	3,427	5,394	5,318	7,945	4,328
Total current assets	197,769	136,698	124,499	319,684	276,809	202,687
Property and equipment, net	25,435	21,920	17,857	16,494	14,314	13,136
Right-of-use asset	36,064	33,458	15,485	13,510	33,349	28,478
Total assets	261,584	193,855	159,356	351,281	393,050	252,281
Accounts payable	634	574	2,566	1,604	3,996	5,013
Accrued liabilities	14,205	10,950	7,816	16,823	14,171	12,098
Total current liabilities	26,766	50,981	72,591	64,508	49,788	26,541
Lease liability, non-current	43,409	38,608	20,294	17,093	36,499	28,659
Total liabilities	107,264	98,800	100,336	114,961	93,290	56,200
Accumulated deficit	(275,907)	(347,104)	(393,512)	(261,182)	(326,184)	(445,905)
Total stockholders' equity	154,320	95,055	59,020	236,320	299,760	196,081
Total liabilities and equity	261,584	193,855	159,356	351,281	393,050	252,281
Common shares outstanding (cover page) thousands of shares	37,654	38,115	43,293	54,301	55,207	59,599

Fiscal years (VYGR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	36,741	(71,197)	(46,408)	132,330	(65,002)	(119,721)
Stock-based compensation	14,934	11,324	9,344	11,153	14,785	14,787
Net cash from operating activities	(96,716)	(53,525)	(12,509)	77,919	(15,310)	(132,467)
Purchases of property and equipment	12,097	1,609	2,491	3,256	3,521	2,596
Net cash from investing activities	112,995	65,906	(7,339)	(141,643)	(94,859)	125,446
Proceeds from issuing common stock	—	—	—	—	93,473	—
Net cash from financing activities	3,163	612	1,110	33,645	114,015	816
Net change in cash	19,442	12,993	(18,738)	(30,079)	3,846	(6,205)

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Voyager Therapeutics	35,769	3,165	(25,842)*	61.6M	4.5 quarters	Q2 FY26 10-QJun 30, 2026
Eledon Pharmaceuticals	6,803	not reported	(22,677)*	81.3M	3.9 quarters	Q2 FY26 10-QJun 30, 2026
Puma Biotechnology	36,537	56,502	1,624*	51.6M	—	Q2 FY26 10-QJun 30, 2026
Neurogene	112,485	not reported	(23,761)*	20.0M	9.5 quarters	Q2 FY26 10-QJun 30, 2026
Aclaris Therapeutics	19,167	1,629	(19,847)*	147.2M	4.6 quarters	Q2 FY26 10-QJun 30, 2026
Alpha Cognition	41,384	6,093	(6,859)*	21.8M	6.0 quarters	Q2 FY26 10-QJun 30, 2026
Vistagen Therapeutics	16,991	not reported	(14,707)	44.4M	2.2 quarters	Q1 FY27 10-QJun 30, 2026
Sangamo Therapeutics	27,586	1,442	(19,282)	414.3M	1.4 quarters	Q1 FY26 10-QMar 31, 2026
Agenus	18,738	34,518	(31,199)*	45.0M	0.6 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.